NCT03591549: Fulvestrant in Metastatic Breast Cancer

NCT03591549
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Ph+ase 4
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 30 Years to 55 Years (Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with brain metastasis
https://ClinicalTrials.gov/show/NCT03591549

Comments are closed.

Up ↑